Gene expression profiling and clinical outcome in breast cancer

OMICS A Journal of Integrative Biology

Volumn 10, Issue 4, 2006, Pages 429-443

  Bertucci, François ^a,b   Finetti, Pascal ^b   Cervera, Nathalie ^b   Maraninchi, Dominique ^a   Viens, Patrice ^a   Birnbaum, Daniel ^b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSTITUT PAOLI CALMETTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; RNA;

BREAST CANCER; CANCER DIAGNOSIS; CANCER GENETICS; CANCER RESEARCH; DIAGNOSTIC PROCEDURE; DNA DETERMINATION; DNA MICROARRAY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; MEDICAL DOCUMENTATION; METHODOLOGY; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RNA ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; PROGNOSIS; TREATMENT OUTCOME;

EID: 33846610579     PISSN: 15362310     EISSN: None     Source Type: Journal    
DOI: 10.1089/omi.2006.10.429     Document Type: Review

References (85)

1. AHMED, A.A., and BRENTON, J.D. (2005). Microarrays and breast cancer clinical studies: forgetting what we have not yet learnt. Breast Cancer Res 7, 96-99.
2. AL-HAJJ, M., WICHA, M.S., BENITO-HERNANDEZ, A., MORRISON, S.J., and CLARKE, M.F. (2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100, 3983-3988.
3. ALBERTSON, D.G., YLSTRA, B., SEGRAVES, R., COLLINS, C., DAIRKEE, S.H., KOWBEL, D., et al. (2000). Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 25, 144-146.
4. ANDERSON, K., HESS, K.R., KAPOOR, M., TIRRELL, S., COURTEMANCHE, J., WANG, B., et al. (2006). Reproducibility of gene expression signature-based predictions in replicate experiments. Clin Cancer Res 12, 1721-1727.
5. AYERS, M., SYMMANS, W.F., STEC, J., DAMOKOSH, A.I., CLARK, E., HESS, K., et al. (2004). Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22, 2284-2293.
6. BERTUCCI, F., BIRNBAUM, D., and GONCALVES, A. (2006). Proteomics of breast cancer: principles and potential clinical applications. Mol Cell Proteomics, 5, 1772-1786.
7. BERTUCCI, F., BORIE, N., GINESTIER, C., GROULET, A., CHARAFE-JAUFFRET, E., ADELAIDE, J., et al. (2004b). Identification and validation of an ERBB2 gene expression signature in breast cancers. Oncogene 23, 2564-2575.
8. BERTUCCI, F., FINETTI, P., ROUGEMONT, J., CHARAFE-JAUFFRET, E., CERVERA, N., TARPIN, C., et al. (2005). Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 65, 2170-2178.
9. BERTUCCI, F., FINETTI, P., ROUGEMONT, J., CHARAFE-JAUFFRET, E., NASSER, V., LORIOD, B., et al. (2004a). Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 64, 8558-8565.
10. BERTUCCI, F., HOULGATTE, R., BENZIANE, A., GRANJEAUD, S., ADELAIDE, J., TAGETT, R., et al. (2000). Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum Mol Genet 9, 2981-2991.
11. BERTUCCI, F., NASSER, V., GRANJEAUD, S., EISINGER, F., ADELAIDE, J., TAGETT, R., et al. (2002). Gene expression profiles of poor-prognosis primary breast cancer correlate with survival. Hum Mol Genet 11, 863-872.
12. BERTUCCI, F., VIENS, P., HINGAMP, P., NASSER, V., HOULGATTE, R., and BIRNBAUM, D. (2003). Breast cancer revisited using DNA array-based gene expression profiling. Int J Cancer 103, 565-571.
13. BRAZMA, A., and VILO, J. (2000). Gene expression data analysis. FEBS Lett 480, 17-24.
14. BUCHHOLZ, T.A., STIVERS, D.N., STEC, J., AYERS, M., CLARK, E., BOLT, A., et al. (2002). Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J 8, 461-468.
15. CAREY, L.A., PEROU, C.M., LIVASY, C.A., DRESSLER, L.G., COWAN, D., CONWAY, K., et al. (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295, 2492-2502.
16. CARTER, S.L., EKLUND, A.C., MECHAM, B.H., KOHANE, I.S., and SZALLASI, Z. (2005). Redefinition of Affymetrix probe sets by sequence overlap with cDNA microarray probes reduces cross-platform inconsistencies in cancer-associated gene expression measurements. BMC Bioinformatics 6, 107.
17. CHANG, J.C., WOOTEN, E.C., TSIMELZON, A., HILSENBECK, S.G., GUTIERREZ, M.C., ELLEDGE, R., et al. (2003). Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362, 362-369.
18. CHANG, J.C., WOOTEN, E.C., TSIMELZON, A., HILSENBECK, S.G., GUTIERREZ, M.C., THAM, Y.L., et al. (2005). Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 23, 1169-1177.
19. DOBBIN, K.K., BEER, D.G., MEYERSON, M., YEATMAN, T.J., GERALD, W. L., JACOBSON, J.W., et al. (2005). Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res 11, 565-572.
20. DONTU, G., AL-HAJJ, M., ABDALLAH, W.M., CLARKE, M.F., and WICHA, M.S. (2003). Stem cells in normal breast development and breast cancer. Cell Prolif 36, Suppl 1, 59-72.
21. EBCTCG (Early Breast Cancer Trialists' Collaborative Group) (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365, 1687-1717.
22. EIFEL, P., AXELSON, J.A., COSTA, J., CROWLEY, J., CURRAN, W.J., Jr., DESHLER, A., et al. (2001). National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93, 979-989.
23. EIN-DOR, L., KELA, I., GETZ, G., GIVOL, D., and DOMANY, E. (2005). Outcome signature genes in breast cancer: is there a unique set? Bioinformatics 21, 171-178.
24. ESPINOSA, E., VARA, J.A., REDONDO, A., SANCHEZ, J.J., HARDISSON, D., ZAMORA, P., et al. (2005). Breast cancer prognosis determined by gene expression profiling: a quantitative reverse transcriptase polymerase chain reaction study. J Clin Oncol 23, 7278-7285.
25. FELDMAN, L.D., HORTOBAGYI, G.N., BUZDAR, A.U., AMES, F.C., and BLUMENSCHEIN, G.R. (1986). Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 46, 2578-2581.
26. FOEKENS, J.A., ATKINS, D., ZHANG, Y., SWEEP, F.C., HARBECK, N., PARADISO, A., et al. (2006). Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 24, 1665-1671.
27. FOLGUEIRA, M.A., CARRARO, D.M., BRENTANI, H., PATRAO, D.F., BARBOSA, E.M., NETTO, M.M., et al. (2005). Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 11, 7434-7443.
28. GIANNI, L., ZAMBETTI, M., CLARK, K., BAKER, J., CRONIN, M., WU, J., et al. (2005). Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23, 7265-7277.
29. GOLDHIRSCH, A., WOOD, W.C., GELBER, R.D., COATES, A.S., THURLIMANN, B., and SENN, H.-J. (2003). Meeting Highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21, 3357-3365.
30. GRANJEAUD, S., BERTUCCI, F., and JORDAN, B.R. (1999). Expression profiling: DNA arrays in many guises. Bioessays 21, 781-790.
31. GRUVBERGER, S., RINGNER, M., CHEN, Y., PANAVALLY, S., SAAL, L.H., BORG, A., et al. (2001). Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61, 5979-5984.
32. HANNEMANN, J., OOSTERKAMP, H.M., BOSCH, C.A., VELDS, A., WESSELS, L.F., LOO, C., et al. (2005). Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 23, 3331-3342.
33. HAYES, D. F. (2005). Prognostic and predictive factors revisited. Breast 14, 493-499.
34. HENDERSON, I.C., BERRY, D.A., DEMETRI, G.D., CIRRINCIONE, C.T., GOLDSTEIN, L.J., MARTINO, S., et al. (2003). Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21, 976-983.
35. HU, Z., FAN, C., OH, D.S., MARRON, J.S., HE, X., QAQISH, B.F., et al. (2006). The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7, 96.
36. HUANG, E., CHENG, S.H., DRESSMAN, H., PITTMAN, J., TSOU, M.H., HORNG, C.F., et al. (2003). Gene expression predictors of breast cancer outcomes. Lancet 361, 1590-1596.
37. IWAO-KOIZUMI, K., MATOBA, R., UENO, N., KIM, S.J., ANDO, A., MIYOSHI, Y., et al. (2005). Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23, 422-431.
38. JANSEN, M.P., FOEKENS, J.A., VAN STAVEREN, I.L., DIRKZWAGER-KIEL, M.M., RITSTIER, K., LOOK, M.P., et al. (2005). Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 23, 732-740.
39. KUO, W.P., JENSSEN, T.K., BUTTE, A.J., OHNO-MACHADO, L., and KOHANE, I.S. (2002). Analysis of matched mRNA measurements from two different microarray technologies. Bioinformatics 18, 405-412.
40. KUO, W.P., LIU, F., TRIMARCHI, J., PUNZO, C., LOMBARDI, M., SARANG, J., et al. (2006). A sequence-oriented comparison of gene expression measurements across different hybridization-based technologies. Nat Biotechnol 24, 832-840.
41. LIANG, P., and PARDEE, A.B. (1992). Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 257, 967-971.
42. LU, J., GETZ, G., MISKA, E.A., ALVAREZ-SAAVEDRA, E., LAMB, J., PECK, D., et al. (2005). MicroRNA expression profiles classify human cancers. Nature 435, 834-838.
43. MA, X.J., WANG, Z., RYAN, P.D., ISAKOFF, S.J., BARMETTLER, A., FULLER, A., et al. (2004). A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5, 607-616.
44. MAH, N., THELIN, A., LU, T., NIKOLAUS, S., KUHBACHER, T., GURBUZ, Y., et al. (2004). A comparison of oligonucleotide and cDNA-based microarray systems. Physiol Genomics 16, 361-370.
45. MAMOUNAS, E.P., BRYANT, J., LEMBERSKY, B., FEHRENBACHER, L., SEDLACEK, S.M., FISHER, B., et al. (2005). Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23, 3686-3696.
46. MAMOUNAS, E.P., and FISHER, B. (2001). Preoperative (neoadjuvant) chemotherapy in patients with breast cancer. Sem Oncol 28, 389-399.
47. MARTIN, M., PIENKOWSKI, T., MACKEY, J., PAWLICKI, M., GUASTALLA, J.P., WEAVER, C., et al. (2005). Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352, 2302-2313.
48. MOYANO, J.V., EVANS, J.R., CHEN, F., LU, M., WERNER, M.E., YEHIELY, F., et al. (2006). AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 116, 261-270.
49. NICHOLSON, R.I., and JOHNSTON, S.R. (2005). Endocrine therapy-current benefits and limitations. Breast Cancer Res Treat 93, Suppl 1, S3-10.
50. OH, D.S., TROESTER, M.A., USARY, J., HU, Z., HE, X., FAN, C., et al. (2006). Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 24, 1656-1664.
51. PAIK, S., KIM, C.Y., SONG, Y.K., and KIM, W.S. (2005). Technology insight: application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer. Nat Clin Pract Oncol 2, 246-254.
52. PAIK, S., SHAK, S., TANG, G., KIM, C., BAKER, J., CRONIN, M., et al. (2004). A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351, 2817-2826.
53. PAWITAN, Y., BJOHLE, J., AMLER, L., BORG, A.L., EGYHAZI, S., HALL, P., et al. (2005). Gene expression profiling spares early breast cancer patients from adjuvant therapy, derived and validated in two population-based cohorts. Breast Cancer Res 7, R953-964.
54. PEROU, C.M., SORLIE, T., EISEN, M.B., VAN DE RIJN, M., JEFFREY, S.S., REES, C.A., et al. (2000). Molecular portraits of human breast tumours. Nature 406, 747-752.
55. PICCART, M.J., LOI, S., VAN'T VEER, L., and AL, E. (2004). Multi-center external validation of the Amsterdam 70-gene prognostic signature in node negative untreated breast cancer: are the results still outperforming the clinicopathological criteria? Breast Cancer Res Treat 88, abstr 38.
56. PICCART-GEBHART, M.J. (2005). Moving away from the "one shoe fits all" strategy: the key to future progress in chemotherapy. J Clin Oncol 23, 1611-1613.
57. QUACKENBUSH, J. (2006). Microarray analysis and tumor classification. N Engl J Med 354, 2463-2472.
58. REIS-FILHO, J.S., WESTBURY, C., and PIERGA, J.Y. (2006). The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol 59, 225-231.
59. RING, A., and DOWSETT, M. (2004). Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11, 643-658.
60. ROCHE, H., FUMOLEAU, P., SPIELMANN, M., et al. (2004). Six cycles of FEC100 vs 3 FEC100 followed by 3 cycles of Docetaxel for node-positive breast cancer patients: analysis at 5 years of the adjuvant PACS01 trial. Breast Cancer Res Treat 88, abstr 112.
61. ROUZIER, R., PEROU, C.M., SYMMANS, W.F., IBRAHIM, N., CRISTOFANILLI, M., ANDERSON, K., et al. (2005a). Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11, 5678-5685.
62. ROUZIER, R., RAJAN, R., WAGNER, P., HESS, K.R., GOLD, D.L., STEC, J., et al. (2005b). Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102, 8315-8320.
63. SACHELARIE, I., GROSSBARD, M.L., CHADHA, M., FELDMAN, S., GHESANI, M., and BLUM, R.H. (2006). Primary systemic therapy of breast cancer. Oncologist 11, 574-589.
64. SCHERF, U., ROSS, D.T., WALTHAM, M., SMITH, L.H., LEE, J.K., TANABE, L., et al. (2000). A gene expression database for the molecular pharmacology of cancer. Nat Genet 24, 236-244.
65. SORLIE, T., PEROU, C.M., TIBSHIRANI, R., AAS, T., GEISLER, S., JOHNSEN, H., et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98, 10869-10874.
66. SORLIE, T., TIBSHIRANI, R., PARKER, J., HASTIE, T., MARRON, J.S., NOBEL, A., et al. (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100, 8418-8423.
67. SORLIE, T., WANG, Y., XIAO, C., JOHNSEN, H., NAUME, B., SAMAHA, R.R., et al. (2006). Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 7, 127.
68. SOTIRIOU, C., NEO, S.Y., MCSHANE, L.M., KORN, E.L., LONG, P.M., JAZAERI, A., et al. (2003). Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100, 10393-10398.
69. SOTIRIOU, C., POWLES, T.J., DOWSETT, M., JAZAERI, A.A., FELDMAN, A.L., ASSERSOHN, L., et al. (2002). Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 4, R3.
70. SOTIRIOU, C., WIRAPATI, P., LOI, S., HARRIS, A., FOX, S., SMEDS, J., et al. (2006). Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98, 262-272.
71. STAUNTON, J.E., SLONIM, D.K., COLLER, H.A., TAMAYO, P., ANGELO, M.J., PARK, J., et al. (2001). Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 98, 10787-10792.
72. TAN, P.K., DOWNEY, T.J., SPITZNAGEL, E.L., Jr., XU, P., FU, D., DIMITROV, D.S., et al. (2003). Evaluation of gene expression measurements from commercial microarray platforms. Nucl Acids Res 31, 5676-5684.
73. TOI, M., HORIGUCHI, K., BANDO, H., SAJI, S., and CHOW, L.W. (2005). Trastuzumab: updates and future issues. Cancer Chemother Pharmacol 56, Suppl 1, 94-99.
74. VAN DE VIJVER, M.J., HE, Y.D., VAN'T VEER, L.J., DAI, H., HART, A.A., VOSKUIL, D.W., et al. (2002). A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347, 1999-2009.
75. VAN LAERE, S.J., VAN DEN EYNDEN, G.G., VAN DER AUWERA, I., VANDENBERGHE, M., VAN DAM, P., VAN MARCK, E.A., et al. (2006). Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res Treat 95, 243-255.
76. VAN'T VEER, L.J., DAI, H., VAN DE VIJVER, M.J., HE, Y.D., HART, A.A., MAO, M., et al. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536.
77. VELCULESCU, V.E., ZHANG, L., VOGELSTEIN, B., and KINZLER, K.W. (1995). Serial analysis of gene expression. Science 270, 484-487.
78. VERONESI, U., BOYLE, P., GOLDHIRSCH, A., ORECCHIA, R., and VIALE, G. (2005). Breast cancer. Lancet 365, 1727-1741.
79. WAGNER, P., WANG, B., CLARK, E., LEE, H., ROUZIER, R., and PUSZTAI, L. (2005). Microtubule Associated Protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo. Cell Cycle 4, 1149-1152.
80. WANG, D.G., FAN, J.B., SIAO, C.J., BERNO, A., YOUNG, P., SAPOLSKY, R., et al. (1998). Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science 280, 1077-1082.
81. WANG, Y., KLIJN, J.G., ZHANG, Y., SIEUWERTS, A.M., LOOK, M.P., YANG, F., et al. (2005). Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365, 671-679.
82. WEST, M., BLANCHETTE, C., DRESSMAN, H., HUANG, E., ISHIDA, S., SPANG, R., et al. (2001). Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 98, 11462-11467.
83. YANG, S.X., SIMON, R.M., TAN, A.R., NGUYEN, D., and SWAIN, S.M. (2005). Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer. Clin Cancer Res 11, 6226-6232.
84. YU, K., LEE, C.H., TAN, P.H., and TAN, P. (2004). Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res 10, 5508-5517.
85. ZAJCHOWSKI, D.A., BARTHOLDI, M.F., GONG, Y., WEBSTER, L., LIU, H.L., MUNISHKIN, A., et al. (2001). Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 61, 5168-5178.